Mucosal immunity and vaccines have gained significant attention due to their potential in preventing infections and treating autoimmune and allergic diseases. The mucosal immune system, which protects mucosal surfaces, is highly specialized and constitutes nearly 80% of all immunocytes in a healthy adult. It includes mucosa-associated lymphoid tissues (MALT), which are crucial for immune responses. The mucosal immune system has three main functions: protecting mucosal surfaces from pathogens, preventing the uptake of antigens, and preventing harmful immune responses to antigens. Mucosal immune responses are compartmentalized and function independently from the systemic immune system. MALT includes structures like Peyer patches, tonsils, and the appendix, which are key sites for initiating immune responses. Antigens are processed and presented by antigen-presenting cells (APCs) to T cells, leading to immune responses. The nature of the antigen and the local environment determine the type of immune response, with T helper 2 (Th2) responses typically occurring for non-pathogenic antigens, while pro-inflammatory responses are induced by pathogens. Mucosal vaccines are effective for preventing infections and treating inflammatory disorders. They induce local immune responses, particularly secretory IgA (SIgA), which is crucial for mucosal defense. Mucosal vaccines can be administered via various routes, including oral, nasal, rectal, and vaginal, each with different efficacy in inducing immune responses. For example, oral vaccines are effective in the gut and mammary glands but less so in the distal colon and genital tract. Nasal vaccines can induce responses in the respiratory and genital mucosae. Effector mechanisms in mucosal immunity include SIgA, which is resistant to proteases and inhibits bacterial adhesion and inflammation. Mucosal cytotoxic T lymphocytes (CTLs) and CD4+ T cells also play roles in immune defense. Regulatory mechanisms, such as the induction of regulatory T cells, help maintain tolerance and prevent autoimmune responses. Mucosal vaccines against infections include oral polio vaccine (OPV), cholera vaccines, typhoid vaccines, and rotavirus vaccines. These vaccines are effective in inducing local immune responses and provide protection against various pathogens. However, challenges remain in developing effective mucosal vaccines, particularly for diseases like HIV and other sexually transmitted infections. Mucosal vaccines for immunotherapy aim to induce tolerance and treat autoimmune and allergic diseases. They have shown promise in preventing and treating conditions like type 1 diabetes and allergic rhinitis. However, challenges in developing safe and effective mucosal vaccines remain, particularly in ensuring their efficacy and safety in diverse populations. The development of mucosal vaccines requires efficient antigen delivery systems and adjuvants that can stimulate the innate immune system and generate effective adaptive immunity. Recent advances in mucosal adjuvants, such as detoxified cholera toxin and CpG oligodeoxynucleotides, show promise in enhancing immune responses. Despite theseMucosal immunity and vaccines have gained significant attention due to their potential in preventing infections and treating autoimmune and allergic diseases. The mucosal immune system, which protects mucosal surfaces, is highly specialized and constitutes nearly 80% of all immunocytes in a healthy adult. It includes mucosa-associated lymphoid tissues (MALT), which are crucial for immune responses. The mucosal immune system has three main functions: protecting mucosal surfaces from pathogens, preventing the uptake of antigens, and preventing harmful immune responses to antigens. Mucosal immune responses are compartmentalized and function independently from the systemic immune system. MALT includes structures like Peyer patches, tonsils, and the appendix, which are key sites for initiating immune responses. Antigens are processed and presented by antigen-presenting cells (APCs) to T cells, leading to immune responses. The nature of the antigen and the local environment determine the type of immune response, with T helper 2 (Th2) responses typically occurring for non-pathogenic antigens, while pro-inflammatory responses are induced by pathogens. Mucosal vaccines are effective for preventing infections and treating inflammatory disorders. They induce local immune responses, particularly secretory IgA (SIgA), which is crucial for mucosal defense. Mucosal vaccines can be administered via various routes, including oral, nasal, rectal, and vaginal, each with different efficacy in inducing immune responses. For example, oral vaccines are effective in the gut and mammary glands but less so in the distal colon and genital tract. Nasal vaccines can induce responses in the respiratory and genital mucosae. Effector mechanisms in mucosal immunity include SIgA, which is resistant to proteases and inhibits bacterial adhesion and inflammation. Mucosal cytotoxic T lymphocytes (CTLs) and CD4+ T cells also play roles in immune defense. Regulatory mechanisms, such as the induction of regulatory T cells, help maintain tolerance and prevent autoimmune responses. Mucosal vaccines against infections include oral polio vaccine (OPV), cholera vaccines, typhoid vaccines, and rotavirus vaccines. These vaccines are effective in inducing local immune responses and provide protection against various pathogens. However, challenges remain in developing effective mucosal vaccines, particularly for diseases like HIV and other sexually transmitted infections. Mucosal vaccines for immunotherapy aim to induce tolerance and treat autoimmune and allergic diseases. They have shown promise in preventing and treating conditions like type 1 diabetes and allergic rhinitis. However, challenges in developing safe and effective mucosal vaccines remain, particularly in ensuring their efficacy and safety in diverse populations. The development of mucosal vaccines requires efficient antigen delivery systems and adjuvants that can stimulate the innate immune system and generate effective adaptive immunity. Recent advances in mucosal adjuvants, such as detoxified cholera toxin and CpG oligodeoxynucleotides, show promise in enhancing immune responses. Despite these